Proactive Investors - Run By Investors For Investors

PreveCeutical Medical unveils promising findings from non-addictive analgesics program

The firm is developing therapies using organic and nature identical products
PreveCeutical Medical unveils promising findings from non-addictive analgesics program
The company currently has five research and development programs on the go

Health sciences group PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) said it had completed a study of peptides to develop as non-addictive painkillers, with promising results.

The firm is developing therapies using organic and nature identical products.

READ: PreveCeutical Medical reports converting acid phytocannabinoids to neutral form

One of its programs is for non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone.

Preveceutical said that via a meticulous process it had now identified five novel peptide constructs, which preferentially target the receptor subtype which is of interest to the company and is purported to avoid addictive and tolerance-inducing side effects.

This subset of peptides has demonstrated potency, in a well-accepted functional dose response assay, that is on par with clinically available agents, such as morphine, the company added.

Chief research officer Dr Harendra Parekh told investors: "We are very pleased with this promising development, as a result of numerous iterations between our peptide design and cell-based screening efforts, we have now yielded a number of constructs which discriminate between the key pain receptors in the body, and importantly, avoid activation of those purported to lead to dependence."

Preveceutical shares in Toronto were unchanged at $0.06 each.

Contact Giles at [email protected]

Follow him on Twitter @Gile74

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use